Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Skin Cancer Diagnostics Market Size Changed, over the years?

The market size for skin cancer diagnostics has experienced robust growth in the recent past. It is projected to increase from $3.13 billion in 2024 to $3.39 billion in 2025, showing a compound annual growth rate (CAGR) of 8.4%. The substantial growth during the historic period is due to factors such as higher incidences of skin cancer, an aging population, awareness and educational campaigns, and government endeavors for early detection.

How Much Will the Skin Cancer Diagnostics Market Be Worth in 2029?

Anticipated to witness robust expansion in the coming years, the skin cancer diagnostics market’s valuation is projected to reach $4.69 billion by 2029, expanding at a compound annual growth rate (CAGR) of 8.4%. The anticipated growth during the projected period is associated with increased awareness about sun exposure, adoption of personalized medicine strategies, the advent of telemedicine and remote monitoring, along with worldwide expansion of the healthcare sector. Primary trends expected during the projected period encompass the incorporation of digital health platforms, the development of novel skin cancer medications, interdisciplinary strategies, advances in dermatopathology, and enhanced patient education and awareness.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11914&type=smp

Which is the Largest Company in the Skin Cancer Diagnostics Market?

Major companies operating in the skin cancer diagnostics market include Pfizer Inc., F. Hoffmann-La Roche Limited, Merck & Co., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Eli Lilly and Company, Canon Medical Systems Corporation, Amgen Inc., GE Healthcare, Daiichi Sankyo Company Limited., National Cancer Institute, Agilent Technologies Inc., bioMerieux SA, Teva Pharmaceutical Industries, Bruker Corp, Almirall, Genentech, Castle Biosciences, Sun Pharmaceutical Industries Limited., American Academy of Dermatology, Biolitec Ag, Alma Lasers, DermTech Inc., SkylineDx BV, DermLite LLC, AMLo Biosciences Limited

What Are the Main Market Drivers in the Skin Cancer Diagnostics Industry?

The skin cancer diagnostics market is projected to expand due to the rising prevalence of melanoma. Melanoma, a form of skin cancer, originates from cells that generate melanin, which has a significant role in determining the color of the skin, hair, and eyes. Diagnostics for skin cancer play a vital role in identifying and assessing skin lesions, thereby facilitating the early detection, accurate diagnosis, and effective treatment of skin cancer. For example, as per a report by the American Cancer Society Inc., a prominent health organization focused on cancer eradication in the US, the count of male melanoma patients in the United States escalated from 57,180 in 2022 to 58,120 in 2023. Additionally, the American Society of Clinical Oncology, a professional body that represents all oncology doctors in the US, stated in March 2023 that melanoma represents about 1% of all skin cancer cases diagnosed in the US. Nonetheless, it accounts for the majority of skin cancer-related deaths. In 2023, melanoma is projected to claim the lives of 7,990 people in the United States, comprising 5,420 men and 2,570 women. Consequently, the mounting incidences of melanoma are propelling the advancement of the skin cancer diagnostics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11914&type=smp

How Is the Skin Cancer Diagnostics Market Segments Structured?

The skin cancer diagnostics market covered in this report is segmented –

1) By Cancer Type: Basal Cell Carcinoma, Squamous Cell Carcinoma, Malignant Melanoma, Other Cancer Types

2) By Type: Diagnosis, Therapeutics

3) By Application: Hospital, Clinic, Laboratory, Other Applications

Subsegments:

1) By Basal Cell Carcinoma: Diagnostic imaging Techniques, Biopsy Procedures, Molecular Diagnostic Tests

2) By Squamous Cell Carcinoma: Diagnostic imaging Techniques, Biopsy Procedures, Molecular Diagnostic Tests

3) By Malignant Melanoma: Diagnostic Imaging Techniques, Biopsy Procedures, Molecular Diagnostic Tests

4) By Other Cancer Types: Non-Melanoma Skin Cancers, Dermatofibrosarcoma Protuberans, Merkel Cell Carcinoma

What Strategic Trends Are Transforming the Skin Cancer Diagnostics Market?

The key players in the skin cancer diagnostics market are pioneering new products such as the PRAME protein, with the aim of improving detection and treatment methods for melanoma and other forms of skin cancer. PRAME, an acronym for Preferentially Expressed Antigen in Melanoma, is a cancer/testis antigen demonstrating promise as a biomarker in melanoma diagnosis. To illustrate, Roche, a global healthcare enterprise based in Switzerland, launched the PRAME (EPR20330) Antibody in October 2022. This melanoma-associated antigen specializes in identifying PRAME protein expression in tissue samples from patients thought to have melanoma. This antibody also plays a crucial role in differentiating between benign and malignant lesions. The identification of PRAME expression indicates malignancy, a pivotal factor in accurate diagnosis and planning of treatment.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/skin-cancer-diagnostics-global-market-report

Which Global Regions Offer the Highest Growth in the Skin Cancer Diagnostics Market?

North America was the largest region in the skin cancer diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the skin cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11914

This Report Delivers Insight On:

1. How big is the skin cancer diagnostics market, and how is it changing globally?

2. Who are the major companies in the skin cancer diagnostics market, and how are they performing?

3. What are the key opportunities and risks in the skin cancer diagnostics market right now?

4. Which products or customer segments are growing the most in the skin cancer diagnostics market?

5. What factors are helping or slowing down the growth of the skin cancer diagnostics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model